GRAIL Clinical Research Program
In order to enable the most accurate early detection of cancer, GRAIL is conducting what we believe to be one of the largest clinical study programs ever pursued in genomic medicine. We are collaborating with leading community and academic medical centers to conduct studies enrolling tens of thousands of people to identify the patterns required to detect many types of cancer, and to validate GRAIL’s products.
We are developing a blood test combining high-intensity genomic sequencing and complex computational algorithms that assess vast amounts of clinical data to find cancer-specific patterns. Our population-scale clinical studies aim to identify the patterns required to detect many types of cancer, and to develop and validate GRAIL’s early detection blood test.
Circulating Cell-free Genome Atlas Study
CCGA is characterizing the landscape of genomic cancer signals in the blood (cell-free nucleic acid (cfNA) profiles) in individuals with and without cancer, and is being used to discover, develop, and validate a blood test designed to detect cancer early...
Current Status: Enrolling
STRIVE will validate a blood test designed to detect cancer early in a group of people without a known cancer diagnosis...
Current Status: Follow-up
SUMMIT will evaluate the ability of a blood test to detect multiple cancer types, including lung cancer, in a diverse population of men and women who do not have a cancer diagnosis at the time of enrollment. It will include a group of individuals at higher risk for cancer due to smoking history.
Current Status: Plans to begin enrolling in 2019